JP2013531630A5 - - Google Patents

Download PDF

Info

Publication number
JP2013531630A5
JP2013531630A5 JP2013511592A JP2013511592A JP2013531630A5 JP 2013531630 A5 JP2013531630 A5 JP 2013531630A5 JP 2013511592 A JP2013511592 A JP 2013511592A JP 2013511592 A JP2013511592 A JP 2013511592A JP 2013531630 A5 JP2013531630 A5 JP 2013531630A5
Authority
JP
Japan
Prior art keywords
antibody preparation
antibody
preparation according
igm
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013511592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531630A (ja
JP6283517B2 (ja
Filing date
Publication date
Priority claimed from GBGB1006753.6A external-priority patent/GB201006753D0/en
Application filed filed Critical
Publication of JP2013531630A publication Critical patent/JP2013531630A/ja
Publication of JP2013531630A5 publication Critical patent/JP2013531630A5/ja
Application granted granted Critical
Publication of JP6283517B2 publication Critical patent/JP6283517B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013511592A 2010-04-22 2011-04-21 抗体調製物 Active JP6283517B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1006753.6 2010-04-22
GBGB1006753.6A GB201006753D0 (en) 2010-04-22 2010-04-22 Process for preparing an immunolobulin composition
PCT/EP2011/056487 WO2011131787A2 (en) 2010-04-22 2011-04-21 Antibody preparations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016118887A Division JP6612186B2 (ja) 2010-04-22 2016-06-15 抗体調製物

Publications (3)

Publication Number Publication Date
JP2013531630A JP2013531630A (ja) 2013-08-08
JP2013531630A5 true JP2013531630A5 (enExample) 2014-06-05
JP6283517B2 JP6283517B2 (ja) 2018-02-21

Family

ID=42270688

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013511592A Active JP6283517B2 (ja) 2010-04-22 2011-04-21 抗体調製物
JP2013511591A Active JP6118248B2 (ja) 2010-04-22 2011-04-21 免疫グロブリン組成物を調製するためのプロセス
JP2016110121A Active JP6612182B2 (ja) 2010-04-22 2016-06-01 免疫グロブリン組成物を調製するためのプロセス
JP2016118887A Active JP6612186B2 (ja) 2010-04-22 2016-06-15 抗体調製物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013511591A Active JP6118248B2 (ja) 2010-04-22 2011-04-21 免疫グロブリン組成物を調製するためのプロセス
JP2016110121A Active JP6612182B2 (ja) 2010-04-22 2016-06-01 免疫グロブリン組成物を調製するためのプロセス
JP2016118887A Active JP6612186B2 (ja) 2010-04-22 2016-06-15 抗体調製物

Country Status (18)

Country Link
US (6) US8900806B2 (enExample)
EP (2) EP2560682B2 (enExample)
JP (4) JP6283517B2 (enExample)
KR (2) KR101872747B1 (enExample)
CN (3) CN102939111B (enExample)
AU (2) AU2011244241B2 (enExample)
CA (2) CA2796263C (enExample)
CO (2) CO6640239A2 (enExample)
ES (2) ES2551605T5 (enExample)
GB (1) GB201006753D0 (enExample)
HU (2) HUE025853T2 (enExample)
IL (2) IL222374A (enExample)
MX (2) MX337060B (enExample)
PL (2) PL2560691T3 (enExample)
RU (4) RU2612899C2 (enExample)
SG (2) SG184843A1 (enExample)
WO (2) WO2011131787A2 (enExample)
ZA (2) ZA201208541B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
FR2959821B1 (fr) * 2010-05-05 2012-07-06 Lab Francais Du Fractionnement Procede de mesure de l'activation du complement par des igg
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
FR2977893B1 (fr) * 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
EP2636684A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
CN104254542A (zh) * 2012-03-09 2014-12-31 瑞士杰特贝林生物制品有限公司 包含分泌-样免疫球蛋白的组合物
KR20150115639A (ko) * 2014-04-04 2015-10-14 전숙영 치료용 면역글로불린 제제 제조에 사용되는 산성 완충액, 이를 이용한 치료용 면역글로불린 제제 제조방법 및 이 제조방법으로 제조된 치료용 면역글로불린 제제
WO2016011054A2 (en) * 2014-07-15 2016-01-21 The Regents Of The University Of California Novel treatment for polycystic kidney disease
ES2964640T3 (es) 2015-08-13 2024-04-08 Amgen Inc Filtración en profundidad cargada de proteínas de unión al antígeno
EP3851123A1 (en) * 2016-03-14 2021-07-21 Biotest AG Treatment of severe community acquired pneumonia
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
RU2660584C1 (ru) * 2017-06-06 2018-07-06 Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" Способ определения FC-функции препаратов иммуноглобулина человека
JP7161534B2 (ja) * 2017-11-29 2022-10-26 エフ.ホフマン-ラ ロシュ アーゲー 標的による干渉が抑制された抗薬物抗体アッセイ
EP3747903A1 (en) 2019-06-07 2020-12-09 Biotest AG Method and kit for testing potency of immunoglobulin compositions
CA3173861A1 (en) * 2020-04-10 2021-10-14 Rudolf Ubelhart Natural antibodies in prophylaxis and therapy
CA3180876A1 (en) * 2020-06-03 2021-12-09 Grifols Worldwide Operations Limited Hyperimmune igg and/or igm compositions and method for preparing thereof and method for obtaining hyperimmune human plasma from a donor
JP2023532473A (ja) * 2020-07-10 2023-07-28 グリフォルス・ワールドワイド・オペレーションズ・リミテッド ヒト血漿由来免疫グロブリンmを含む組成物を得るための方法
CN111944043B (zh) * 2020-09-01 2023-05-09 华兰生物工程重庆有限公司 一种从血浆废弃物中提取IgM的方法
CA3195385A1 (en) 2020-11-19 2022-05-27 Biotest Ag Method and kit for testing immunomodulatory potency of immunoglobulin compositions, e.g., for treatment of covid-19
MX2024001187A (es) 2021-07-29 2024-02-27 Csl Behring Ag Metodo para purificar inmunoglobulina g y usos de la misma.
KR20250161658A (ko) 2023-03-29 2025-11-17 체에스엘 베링 아게 부작용과 관련된 면역글로불린을 식별하는 방법
AU2024290612A1 (en) 2023-07-04 2026-02-05 Csl Behring Ag Method of purification
WO2025229607A1 (en) 2024-05-03 2025-11-06 Csl Behring Ag Systems and methods for solid-liquid separation
WO2026074476A1 (en) 2024-10-02 2026-04-09 Csl Behring Ag Method of detecting autoantibodies against fc epsilon receptor i
WO2026078636A1 (en) 2024-10-11 2026-04-16 Csl Behring Ag Methods of monitoring chromatographic purification of proteins
WO2026093923A1 (en) 2024-10-29 2026-05-07 Csl Behring Ag Method for detection of a plasma protein

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US136556A (en) 1873-03-04 Improvements in button-fastenings
DE2901822A1 (de) 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
US4371520A (en) * 1981-10-28 1983-02-01 The Green Cross Corporation Process for preparing immunoglobulin suitable for intravenous injection
DE3310150A1 (de) * 1983-03-21 1984-09-27 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung einer nebenwirkungsfreien igg-immunglobulinloesung fuer die intravenoese applikation
IL90281A (en) 1988-06-06 1994-10-07 Miles Inc Preparations containing MGI antibodies
DE3825429C2 (de) 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US4939176A (en) 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
DE3927112C1 (enExample) † 1989-08-17 1990-10-25 Biotest Pharma Gmbh, 6072 Dreieich, De
DE3927111C3 (de) * 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
US5256771A (en) * 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
US5367054A (en) * 1993-04-12 1994-11-22 Stolle Research & Development Corp. Large-scale purification of egg immunoglobulin
US6190608B1 (en) 1995-07-14 2001-02-20 Croix-Rouge De Beligique Departement Central De Fractionnement Method and apparatus for inactivating contaminants in blood products
DE59509979D1 (de) 1995-09-22 2002-02-07 Zlb Bioplasma Ag Bern Verfahren zur Gewinnung von Immunglobulinen aus Fraktionen, die bei der Fraktionierung von menschlichem Blutplasma entstehen
EP0835880A1 (de) 1996-10-14 1998-04-15 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation
JP3987599B2 (ja) * 1996-12-05 2007-10-10 日本製薬株式会社 筋ジストロフィー治療剤
JPH10167894A (ja) * 1996-12-11 1998-06-23 Mitsubishi Gas Chem Co Inc ビスマス置換希土類鉄ガーネット単結晶膜の製造法
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
ID27417A (id) * 1998-06-09 2001-04-05 Statens Seruminstitut Proses untuk memproduksi immunoglobulin untuk pemberian melalui intravena dan produk-produk immunoglobulin lainnya
RU2178309C2 (ru) * 2000-01-12 2002-01-20 Российский научно-исследовательский институт геронтологии Антитимоцитарный глобулин для внутривенного введения и способ его получения
RU2192279C2 (ru) * 2000-09-07 2002-11-10 Нижегородское государственное предприятие по производству бактерийных препаратов Способ получения иммуноглобулинового препарата
AU2954502A (en) 2000-11-13 2002-05-21 Bayer Ag Method of inactivating microorganisms in a fluid using ultraviolet radiation
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US7727974B2 (en) 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
WO2003037504A1 (en) 2001-11-02 2003-05-08 Japan Techno Co., Ltd. Vibratory stirrer for sterilization and sterilizer and sterilization method employing vibratory stirrer
RU2255766C2 (ru) * 2003-03-05 2005-07-10 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габрического Министерства здравоохранения Российской Федерации" Способ получения иммуноглобулинового препарата для профилактики и терапии бактериальных и вирусных инфекций, иммуноглобулиновый препарат для профилактики и терапии бактериальных и вирусных инфекций (варианты) и суппозитории на основе иммуноглобулинового препарата
EP1615946B1 (en) 2003-03-26 2020-05-06 Sudhir Paul Proteolytic and covalent antibodies
BRPI0415887B1 (pt) 2003-10-27 2021-01-26 Wyeth métodos para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
CA2557229C (en) 2004-02-27 2012-07-10 Octapharma Ag A method of providing a purified, virus safe antibody preparation
DE602005021694D1 (de) 2004-12-10 2010-07-15 Novimmune Sa Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung
WO2006064373A2 (en) 2004-12-16 2006-06-22 Genzyme Polyclonals S.A.S. Methods of purifying immunologlobulins
KR101157174B1 (ko) 2005-11-24 2012-06-20 삼성전자주식회사 세포 또는 바이러스의 신속한 파괴 방법 및 장치
DE102005062634A1 (de) 2005-12-23 2007-06-28 Blutspendedienst der Landesverbände des Deutschen Roten Kreuzes Niedersachsen, Sachsen-Anhalt, Thüringen, Oldenburg und Bremen gGmbH Verfahren zur Inaktivierung von Pathogenen in Spenderblut, Blutplasma oder Erythrozytenkonzentraten in flexiblen Behältnissen unter Bewegung
FR2899112B1 (fr) * 2006-03-31 2010-09-03 Lab Francais Du Fractionnement Concentre d'immunoglobulines et de fragments f (ab)'2 et/ou fab specifiques d'un arbovirus en tant que medicament.
FR2899111B1 (fr) 2006-03-31 2010-09-03 Lab Francais Du Fractionnement Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament.
US8354076B2 (en) 2006-10-02 2013-01-15 Palo Alto Research Center Incorporated Fluid stirring mechanism
EP1950225A1 (de) 2007-01-25 2008-07-30 Octapharma AG Verfahren zur Steigerung von Proteinausbeuten
WO2009140236A2 (en) 2008-05-12 2009-11-19 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
RU2457863C2 (ru) * 2008-08-05 2012-08-10 Виктор Владимирович Чалов Композиция, обладающая противовирусным и антимикробным действием, содержащая консорциум иммуноглобулинов
RU2457861C2 (ru) * 2008-08-05 2012-08-10 Виктор Владимирович Чалов Композиция, обладающая противовирусным и антимикробным действием, содержащая консорциум иммуноглобулинов
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
NZ591514A (en) 2011-03-03 2013-11-29 Kode Biotech Ltd Assay method

Similar Documents

Publication Publication Date Title
RU2012149741A (ru) Препараты антител
AP257A (en) A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy.
TWI531576B (zh) 以基因轉殖合成的第七凝血因子之純化方法
CN111454354A (zh) 抗2019-nCoV的抗体、制剂及其制备方法和应用
IL272779B1 (en) Methods of inactivating viral contaminants
CN114591918B (zh) 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途
CN114591917A (zh) 产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途
Valdés et al. A summary of the manufacture, biochemical characterization, and virological safety demonstration of the mouse mAb CB. Hep-1 used to produce the hepatitis B vaccine
CN121609787A (zh) 抗水痘-带状疱疹病毒的抗体及其应用
HK1177600B (en) Process for preparing an immunoglobulin composition